The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma
OBJECTIVES: I. Evaluate the safety of multiple (2-3) administrations of technetium Tc 99m
LL2 monoclonal antibody (LymphoScan) in patients with B-cell non-Hodgkin's lymphoma after
chemotherapy and/or radiotherapy. II. Describe human antimouse antibody production in these
patients. III. Demonstrate that addition of a single LymphoScan study to conventional
diagnostic modalities (CDMs) can differentiate between tumor and residual scarring. IV.
Determine the diagnostic operating characteristics of LymphoScan to detect residual tumor in
patients with radiologically detectable masses. V. Compare patient management plans based on
CDMs alone and both CDMs and LymphoScan.
OUTLINE: This is an open label, multicenter study. Patients receive an infusion of
technetium Tc 99m LL2 monoclonal antibody (LymphoScan) by IV injection or infused over 20-30
minutes after completion of therapy as part of the response evaluation procedures. Planar
images are acquired between 4-8 hours and 18-24 hours following antibody injection, and
single photon emission computerized tomography (SPECT) imaging is performed between 4-8
hours following antibody injection. Patients may receive a repeat injection of LymphoScan.
Patients are followed for 3 to 6 months.
PROJECTED ACCRUAL: There will be 60 patients accrued into this study.
Primary Purpose: Diagnostic
William A. Wegener, MD, PhD
United States: Federal Government
|Marlene & Stewart Greenebaum Cancer Center, University of Maryland||Baltimore, Maryland 21201|
|Cedars-Sinai Medical Center||Los Angeles, California 90048|
|University of Texas- Houston Medical School||Houston, Texas 77030|
|Nuclear Physicians Ltd.||Cuyahoga Falls, Ohio 44223|